Quinolinic Acid / 5-HIAA Ratio

Researchers have found changes in urinary quinolinic acid and 5-HIAA in small studies of depression, bowel disorders, fatigue, and migraine. Most of these studies examined the individual compounds or other ratios. Most also come from one research group in Poland, and independent replication is lacking. Their findings don't establish that the quinolinic acid/5-HIAA ratio can identify the cause of your symptoms.

This is an exploratory marker. Its usefulness for diagnosis, prevention, or treatment monitoring hasn't been established, and there is no validated treatment target. The chemistry can be measured accurately without its clinical meaning being settled.

What the Two Compounds Represent

Tryptophan is a building block of protein that you get from food. Your body also uses it to make serotonin and to produce other compounds through the kynurenine pathway. This pathway handles much of tryptophan breakdown and contributes to making NAD+. Cells use NAD+ to process energy.

5-HIAA forms when your body breaks down serotonin. Much of the body's serotonin is produced in the gut, so urinary 5-HIAA reflects processes outside the brain. Quinolinic acid forms along the kynurenine pathway and can be used to make NAD+. It is a normal part of metabolism, although its accumulation can matter in disease.

This test measures both compounds in urine using liquid chromatography–mass spectrometry, or LC-MS, and calculates quinolinic acid divided by 5-HIAA. The method separates compounds and identifies them through their molecular mass signals.

A higher ratio can result from more quinolinic acid, less 5-HIAA, or both. A lower ratio can result from the opposite changes. If both compounds change in the same proportion, the ratio stays the same. The individual results therefore matter when you interpret a change.

How Inflammation Fits

Inflammation can change tryptophan metabolism. Experiments with cultured human immune cells found that interferon-gamma increased their conversion of tryptophan into quinolinic acid, depending on dose and time. Interferon-gamma is a signaling protein that immune cells release during inflammation. That supports a biological connection, but it doesn't make this urinary ratio a direct measure of inflammation or prove that your body is making too little serotonin.

Urinary amounts depend on production, further breakdown, and kidney handling. Mouse studies linked quinolinic acid build-up to impaired conversion into NAD+, and human studies have used a related urinary ratio as an indirect marker of this. An increase can therefore have several explanations beyond increased inflammatory activity.

Low Mood and Depression

A study of 90 adults compared younger adults, older adults without mood disorders, and older adults with mild to moderate depression. The depressed older group had higher urinary quinolinic acid than the healthy older group. However, urinary 5-HIAA did not differ significantly between the groups. This supports an association involving quinolinic acid, without establishing the proposed combination of higher quinolinic acid and lower serotonin breakdown.

The study measured urine compounds using LC-MS/MS, which is directly relevant to the components of this test. It did not validate the quinolinic acid/5-HIAA ratio as a depression test or establish that the metabolic differences caused the mood symptoms.

Bowel Symptoms and Fatigue

A study of 120 people compared constipation-predominant irritable bowel syndrome, diarrhea-predominant irritable bowel syndrome, and healthy controls. Urinary quinolinic acid was higher in both bowel-disorder groups, particularly the constipation group. Urinary 5-HIAA was higher in the diarrhea group but did not differ significantly between the constipation group and controls. Within the constipation group, higher quinolinic acid was associated with worse depression scores.

Another study compared 80 women with unclassified irritable bowel syndrome, half of whom also had chronic fatigue syndrome. Those with chronic fatigue syndrome had higher urinary quinolinic acid and lower 5-HIAA. These were group differences measured with LC-MS/MS. They don't establish a ratio that diagnoses chronic fatigue syndrome, distinguishes bowel-disorder subtypes, or identifies gut inflammation in an individual.

Migraine

In a study of 21 people with episodic migraine and 32 controls, urine collected between attacks showed lower 5-HIAA and higher quinolinic acid in the migraine group. Lower 5-HIAA was associated with more frequent headaches and greater migraine-related disability. This small LC-MS/MS study did not establish whether the ratio predicts attacks or changes reliably with successful treatment.

Other migraine research points in different directions. Blood studies found lower, not higher, quinolinic acid between attacks in migraine without aura and in chronic migraine, and older urinary 5-HIAA studies found increases, decreases, or no difference during attacks. Direction of change varies by specimen and migraine type.

Severe Illness and Chronic Pain

Urinary quinolinic acid has also been studied during severe illness and after surgery. In human studies, a higher urinary quinolinic acid-to-tryptophan ratio was associated with acute kidney injury. That is a different ratio, and its findings cannot be transferred to quinolinic acid/5-HIAA.

A retrospective laboratory study of 17,834 samples from people with chronic pain reported elevated quinolinic acid in 29%, using that laboratory's own criteria. The analysis was run by the commercial laboratory that performed the testing, a potential conflict of interest. It did not evaluate medications or other illnesses as possible explanations. It neither established quinolinic acid as a cause of pain nor validated this ratio for pain management.

Urine and Brain Chemistry Are Different Measurements

Quinolinic acid can activate NMDA receptors involved in nerve signaling. Laboratory experiments, including studies that injected quinolinic acid directly into rat brains, have shown nerve-cell injury. Those experiments don't establish that a higher urinary result means your brain is exposed to damaging concentrations.

Human brain-disease research also varies by condition and specimen. A systematic review of multiple sclerosis studies reported higher quinolinic acid in the fluid surrounding the brain and spinal cord. A separate meta-analysis found lower concentrations in that fluid in Alzheimer's dementia. Neither finding validates a urinary ratio as a measure of brain damage or future dementia risk.

Interpreting a Higher or Lower Result

There is no established rule that lower is healthier. Low urinary 5-HIAA does not establish a serotonin shortage in your brain, and high quinolinic acid does not establish inflammation as the cause of your symptoms. A ratio can also conceal changes when both components rise or fall together.

Standalone 5-HIAA has an established clinical use in evaluating carcinoid syndrome caused by some serotonin-producing neuroendocrine tumors. That evidence applies to dedicated 5-HIAA testing with its own collection and interpretation procedures. A low quinolinic acid/5-HIAA ratio is not a validated cancer-screening result.

When Results Can Be Misleading

• Recent illness and surgery: These can change tryptophan metabolism and urinary quinolinic acid. A result during illness may reflect that temporary state; the direction of the full ratio isn't predictable from quinolinic acid alone.
• Food and supplements: Serotonin-rich foods such as bananas, pineapple, and walnuts can increase urinary 5-HIAA, and supplements containing 5-HTP or tryptophan can affect its production. Dietary effects can change the ratio without demonstrating a change in inflammation.
• Medications: 5-HIAA is the more drug-sensitive half of the ratio. Acetaminophen, guaifenesin, diazepam, phenobarbital, caffeine, and nicotine have been reported to raise urinary 5-HIAA. Levodopa, aspirin, phenothiazines, MAO inhibitors, tricyclic antidepressants, isoniazid, and methyldopa have been reported to lower it. Other antidepressants, antipsychotics, anti-nausea drugs, and migraine medicines can also shift it. LC-MS largely avoids the assay interference seen with older methods, so the drug effects that remain are mostly real biological changes. Older research also found increased urinary quinolinic acid after oral-contraceptive use or vitamin B6 antagonism under tryptophan-loading conditions.
• Malabsorption and gut stasis: Celiac disease, Whipple disease, tropical sprue, and intestinal stasis can raise urinary 5-HIAA, which lowers the ratio without any change in quinolinic acid.
• Kidney function: Reduced kidney function tends to push the two compounds in opposite directions. In rats with kidney insufficiency, blood quinolinic acid rose and its urinary excretion increased about 3.5-fold, while in people urinary 5-HIAA can read falsely low in kidney failure and on dialysis. Together these effects could push the ratio upward. The ratio does not remove them.
• Sample handling: Storage, preservation, and delays before analysis can affect sample stability. A poorly handled specimen can produce a misleading comparison.
• LC-MS limitations: Other substances in urine can suppress or enhance analytical signals. Calibration, sample preparation, and interference checks matter even with this selective method.
• A very small denominator: When 5-HIAA is close to the method's measurement limit, small analytical changes can produce a large change in the calculated ratio.

Some studies report each compound relative to urine creatinine to account for dilution. If both compounds use the same creatinine correction from the same sample, that correction cancels when their ratio is calculated. It doesn't correct for differences in how your kidneys process the two compounds.

What Serial Results Can Show

Repeated measurements can document changes in urine chemistry. There is no established amount of change that proves a meaningful health improvement, however, and a personal baseline doesn't supply a validated treatment target. Matching collection conditions and laboratory methods makes comparisons more interpretable without turning the ratio into a proven treatment-monitoring tool.